Humabs BioMed Seeking Clinical Development Partner For ‘Natural Selection’ MAbs
This article was originally published in The Pink Sheet Daily
Novartis and MedImmune have over the past several months also started clinical studies of antibodies licensed from the Swiss biotech, which derives its products from patients with highly effective immune responses.
You may also be interested in...
The biotech’s senior VP for infectious disease and vaccine R&D says prevention must be a part of fighting antimicrobial resistance, but moving the new approach into advanced trials first requires getting a handle on the incidence of hospital-acquired pneumonia in intensive care patients.
While not as high-profile as some other venture raises over the last year, Novimmune has pulled in CHF 200.5 million in Series B financing over 16 years. Plus, news on raises by Pronutria, Melinta, Argos and Arrowhead.
Denali Therapeutics has reported promising early clinical data in Hunter syndrome for its fusion protein, DNL310, an investigational agent that crosses the blood-brain barrier and is expected to address disease-associated CNS effects; however, some biomarker data disappointed, and there are potential competitors also under development.